Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis
- PMID: 32468162
- DOI: 10.1007/s00404-020-05587-2
Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis
Abstract
Background: Lymph node metastasis is a principal prognostic factor for the treatment of endometrial cancer. Added value of para-aortic lymphadenectomy to only pelvic lymphadenectomy for intermediate/high-risk endometrial cancer patients remains controversial.
Objective: A systematic review and meta-analysis was performed to assess the impact of combined pelvic and para-aortic lymph node dissection (PPALND) compared to only pelvic lymph node dissection (PLND) on survival outcomes of intermediate and/or high-risk patients.
Study design: The systematic review and meta-analysis adhered to the PRISMA guidelines for meta-analyses of interventional studies. Pubmed, Scopus, EMBASE and Cochrane were searched up to April 20, 2018. Included studies were those comparing high-risk endometrial cancer patients that had performed pelvic and para-aortic lymph node dissection (PPALND) vs. only pelvic lymph node dissection (PLND) apart from standard procedure (total hysterectomy with bilateral salpingo-oophorectomy, TAHBSO). Primary outcomes of the study were overall survival and disease-free survival rates. Methodological quality of the included studies was assessed using the ROBINS-I tool. Overall quality of the evidence for the primary and secondary outcomes was evaluated as per GRADE guideline using the GRADE pro GD tool.
Results: There were 13 studies identified with 7349 patients included. All studies were retrospective observational as no RCTs or prospective studies adhering to inclusion criteria were retrieved. Combined pelvic and para-aortic lymphadenectomy was associated with 46% decreased risk for death (HR 0.54, 95% CI 0.35-0.83, I2 = 62.1%) and 49% decreased risk for recurrence (HR 0.51, 95% CI 0.28-0.93). It was also associated with increased 5-year OS rate (RR 1.13, 95% CI 1.04-0.24, I2 = 57.3%) and increased 5-year DFS rate (RR 1.23, 95% CI 1.14-1.31, I2 = 85.5) compared with only pelvic lymphadenectomy.
Conclusion: Combined pelvic and para-aortic lymphadenectomy is associated with improved survival outcomes compared with only pelvic lymphadenectomy in women with intermediate/high-risk endometrial cancers. Further prospective studies should be performed.
Keywords: Disease-free survival; High-risk; Lymphadenectomy; Overall survival; Para-aortic; Pelvic; Recurrence.
Similar articles
-
Therapeutic role of para-aortic lymphadenectomy in patients with intermediate- and high-risk endometrial cancer: a systematic review and meta-analysis.Int J Gynecol Cancer. 2024 Apr 1;34(4):519-527. doi: 10.1136/ijgc-2023-005134. Int J Gynecol Cancer. 2024. PMID: 38296516
-
Survival benefits of pelvic lymphadenectomy versus pelvic and para-aortic lymphadenectomy in patients with endometrial cancer: A meta-analysis.Medicine (Baltimore). 2018 Jan;97(1):e9520. doi: 10.1097/MD.0000000000009520. Medicine (Baltimore). 2018. PMID: 29505525 Free PMC article.
-
Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.Int J Gynecol Cancer. 2010 Aug;20(6):1000-5. doi: 10.1111/IGC.0b013e3181d80aff. Int J Gynecol Cancer. 2010. PMID: 20683408
-
Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis.Lancet. 2010 Apr 3;375(9721):1165-72. doi: 10.1016/S0140-6736(09)62002-X. Epub 2010 Feb 24. Lancet. 2010. PMID: 20188410
-
Role of complete para-aortic lymphadenectomy in endometrial cancer.Curr Opin Obstet Gynecol. 2009 Feb;21(1):10-4. doi: 10.1097/GCO.0b013e32831ac3ac. Curr Opin Obstet Gynecol. 2009. PMID: 19124998 Review.
Cited by
-
A Review of Laparoscopic Para-aortic Lymphadenectomy for Early-stage Endometrial Cancer: Extraperitoneal Approach May Have the Advantage over Intraperitoneal Approach.Gynecol Minim Invasive Ther. 2023 Oct 31;13(1):10-18. doi: 10.4103/gmit.gmit_25_23. eCollection 2024 Jan-Mar. Gynecol Minim Invasive Ther. 2023. PMID: 38487605 Free PMC article. Review.
-
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification.Cancers (Basel). 2021 Nov 22;13(22):5848. doi: 10.3390/cancers13225848. Cancers (Basel). 2021. PMID: 34831000 Free PMC article. Review.
-
Prognostic significance of para-aortic node metastasis in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.J Gynecol Oncol. 2025 Jul;36(4):e57. doi: 10.3802/jgo.2025.36.e57. Epub 2025 Jan 29. J Gynecol Oncol. 2025. PMID: 39924672 Free PMC article. Clinical Trial.
-
Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.J Gynecol Oncol. 2025 Jan;36(1):e3. doi: 10.3802/jgo.2025.36.e3. Epub 2024 Jun 3. J Gynecol Oncol. 2025. PMID: 38857908 Free PMC article. Clinical Trial.
-
[PIK3CA Somatic Mutations Are Associated With Lymph Node Metastasis in Endometrial Cancer].Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Mar 20;56(2):434-441. doi: 10.12182/20250360106. Sichuan Da Xue Xue Bao Yi Xue Ban. 2025. PMID: 40599290 Free PMC article. Chinese.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous